(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.23%) $83.66
(-1.16%) $1.619
(0.10%) $2 349.60
(-0.07%) $27.52
(0.25%) $924.40
(0.36%) $0.935
(0.67%) $11.02
(0.14%) $0.800
(-0.07%) $92.11
3 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas...
Stats | |
---|---|
本日の出来高 | 136.00 |
平均出来高 | 594.00 |
時価総額 | 135.19B |
EPS | €0 ( 2024-04-24 ) |
次の収益日 | ( €0 ) 2024-05-01 |
Last Dividend | €2.13 ( 2023-08-17 ) |
Next Dividend | €0 ( N/A ) |
P/E | 21.63 |
ATR14 | €0.724 (0.29%) |
Amgen Inc 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Amgen Inc 財務諸表
Annual | 2023 |
収益: | €28.19B |
総利益: | €19.74B (70.02 %) |
EPS: | €12.56 |
FY | 2023 |
収益: | €28.19B |
総利益: | €19.74B (70.02 %) |
EPS: | €12.56 |
FY | 2022 |
収益: | €26.32B |
総利益: | €19.92B (75.66 %) |
EPS: | €12.18 |
FY | 2021 |
収益: | €25.98B |
総利益: | €19.53B (75.16 %) |
EPS: | €9.74 |
Financial Reports:
No articles found.
Amgen Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€1.940 (N/A) |
€1.940 (N/A) |
€2.13 (N/A) |
€2.13 (N/A) |
€2.13 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.280 | 2011-08-16 |
Last Dividend | €2.13 | 2023-08-17 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 49 | -- |
Total Paid Out | €56.75 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.22 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.55 | |
Div. Directional Score | 7.43 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
V6C.DE | Ex Dividend Junior | 2023-06-01 | Annually | 0 | 0.00% | |
ELG.DE | Ex Dividend Knight | 2023-05-11 | Annually | 0 | 0.00% | |
NTH.DE | Ex Dividend Knight | 2023-08-25 | Quarterly | 0 | 0.00% | |
AEIN.DE | Ex Dividend Knight | 2023-06-14 | Annually | 0 | 0.00% | |
GOB.DE | Ex Dividend Knight | 2023-06-12 | Sporadic | 0 | 0.00% | |
PSQ.F | Ex Dividend Knight | 2023-08-23 | Semi-Annually | 0 | 0.00% | |
BLQA.DE | Ex Dividend Knight | 2023-09-07 | Quarterly | 0 | 0.00% | |
INH.DE | Ex Dividend Knight | 2023-05-18 | Annually | 0 | 0.00% | |
ST5.DE | No Dividend Player | 2023-06-26 | Annually | 0 | 0.00% | |
CTO.DE | Ex Dividend Knight | 2023-08-24 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.238 | 1.500 | 5.23 | 7.85 | [0 - 0.5] |
returnOnAssetsTTM | 0.0691 | 1.200 | 7.70 | 9.23 | [0 - 0.3] |
returnOnEquityTTM | 1.033 | 1.500 | 10.00 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.678 | -1.000 | 3.22 | -3.22 | [0 - 1] |
currentRatioTTM | 1.649 | 0.800 | 6.75 | 5.40 | [1 - 3] |
quickRatioTTM | 1.027 | 0.800 | 8.67 | 6.93 | [0.8 - 2.5] |
cashRatioTTM | 0.595 | 1.500 | 7.81 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.665 | -1.500 | 10.00 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 3.15 | 1.000 | 9.94 | 9.94 | [3 - 30] |
operatingCashFlowPerShareTTM | 15.83 | 2.00 | 4.72 | 9.44 | [0 - 30] |
freeCashFlowPerShareTTM | 13.76 | 2.00 | 3.12 | 6.24 | [0 - 20] |
debtEquityRatioTTM | 10.37 | -1.500 | 10.00 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.700 | 1.000 | 1.663 | 1.663 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.321 | 1.000 | 5.57 | 5.57 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.131 | 1.000 | -0.383 | -0.383 | [0.2 - 2] |
assetTurnoverTTM | 0.290 | 0.800 | -1.399 | -1.119 | [0.5 - 2] |
Total Score | 10.30 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 21.50 | 1.000 | 7.93 | 0 | [1 - 100] |
returnOnEquityTTM | 1.033 | 2.50 | 3.34 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 13.76 | 2.00 | 5.41 | 6.24 | [0 - 30] |
dividendYielPercentageTTM | 3.20 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 15.83 | 2.00 | 4.72 | 9.44 | [0 - 30] |
payoutRatioTTM | 0.678 | 1.500 | 3.22 | -3.22 | [0 - 1] |
pegRatioTTM | -5.58 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.300 | 1.000 | 4.99 | 0 | [0.1 - 0.5] |
Total Score | 4.55 |
Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。